Evidence map›Paper›PMID 40443805›Full record

ArticleFrontiers in toxicology2025

Quantitative adverse outcome pathway modeling for cigarette-smoke-induced airway mucus hypersecretion. Part 1: adverse-outcome-pathway-based

Sakuya Ichikawa, Shugo Muratani, Keigo Sano, Kazuo Erami, Akina Mori, Risa Matsumoto, Shigeaki Ito

Abstract read
In one paragraph

Article in Frontiers in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sakuya IchikawaScientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Kanagawa, Japan.
Shugo MurataniScientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Kanagawa, Japan.
Keigo SanoScientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Kanagawa, Japan.
Kazuo EramiScientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Kanagawa, Japan.
Akina MoriScientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Kanagawa, Japan.
Risa MatsumotoScientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Kanagawa, Japan.
Shigeaki ItoScientific Product Assessment Center, Japan Tobacco Inc., Yokohama, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adverse outcome pathway (AOP)-based chemical risk assessment is a promising tool for regulatory decision-making and is typically used in toxicological assessments. However, it also holds potential for pharmacological and disease-related evaluations. The present study focuses on an AOP for decreased lung function. Lung function is normally robustly maintained by homeostatic capacity, but repeated and chronic stimulation can disrupt this capacity, leading to impaired lung function and mucus hypersecretion. We developed an AOP-based

Indexed as

chronic bronchitisin vitro disease modelingnew approach methodologyrepeated exposuresmoke inhalation

Identifiers

PMID40443805
PMCPMC12119482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.